Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma

In this phase I dose-escalation trial, we assess the maximum tolerated dose (MTD) of Bermekimab in combination with Nanoliposomal Irinotecan (Nal-Iri) and 5-Fluorouracil/Folinic Acid (5-FU/FA). Secondarily, we investigate effects on weight, lean body mass, quality-of-life, the gut microbiome composi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Jun, Thomassian, Shant, Kim, Sungjin, Gresham, Gillian, Moshayedi, Natalie, Ye, Jason Y., Yang, Julianne C., Jacobs, Jonathan P., Lo, Simon, Nissen, Nick, Gaddam, Srinivas, Tighiouart, Mourad, Osipov, Arsen, Hendifar, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440135/
https://www.ncbi.nlm.nih.gov/pubmed/36056179
http://dx.doi.org/10.1038/s41598-022-19401-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440135/
https://www.ncbi.nlm.nih.gov/pubmed/36056179
http://dx.doi.org/10.1038/s41598-022-19401-3

Ejemplares similares